AI assistant
Cartesian Therapeutics, Inc. — Director's Dealing 2024
Jan 4, 2024
33483_dirs_2024-01-04_d02d6a86-35d1-4171-a03f-e61b9bc6800b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2024-01-02
Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-02 | Common Stock | A | 178000 | — | Acquired | 7471625 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-02 | Stock Option (Right to Buy) | $0.6552 | A | 228000 | Acquired | 2034-01-01 | Common Stock (228000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 29868490 | Indirect |
| Common Stock | 86418 | Indirect |
Footnotes
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments so that the underlying shares will be fully vested on January 2, 2027.
F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.
F3: This award will vest in 36 equal monthly installments, so that it shall be fully vested on the third anniversary of the date of grant.